New treatments for stage II membranous nephropathy include calmodulin phosphatase inhibitor and rituximab therapy. Currently, for stage II treatment of membranous nephropathy, according to the 2021 KDIGO glomerulonephropathy guideline, glomerular filtration rate, 24-hour urine protein quantification and serum protein level are risk stratified, and calcineurin phosphatase inhibitors, such as tacrolimus, can be given to intermediate- and high-risk patients, with fewer adverse effects and high drug efficacy. In addition, at present, the application of rituximab in membranous nephropathy is becoming more and more widespread, the evaluation of patients, for intermediate and high-risk patients can also be applied to rituximab treatment, adverse reactions significantly reduced; in addition, for refractory patients can be applied to cyclophosphamide and other drugs. The above medication should be used in accordance with the doctor’s prescription, and should not be used blindly to avoid aggravation of the condition. For patients with membranous nephropathy, they should seek medical treatment in regular hospitals in time and follow the doctor’s instructions for standardized treatment.